assess whether cranial irradiation would have made a difference in CNS relapse, they compared the outcomes of 71 patients whose leukemias would have qualified them for irradiation with the outcomes of 56 patients who had received such irradiation in the past. The researchers found that the 71 patients, in fact, had significantly better complete remission than the 56 patients who had been irradiated.
"The bottom line is that not only did we get outstanding treatment responses in these patients, many of whom would have otherwise received irradiation, but they will have a better quality of life because of the absence of its side effects," Pui said.
"In a way, these findings represent coming full circle," said Dr. William Evans, St. Jude director and CEO and a co-author of the paper. "St. Jude was the first to introduce cranial radiation as a treatment strategy that advanced the cure of childhood ALL to 50 percent. Now, St. Jude is the first to show that we can successfully eliminate irradiation by optimizing chemotherapy."
Other authors of this paper include Deqing Pei, John Sandlund, Sue Kaste, Raul Ribeiro, Jeffrey Rubnitz, Susana Raimondi, Mihaela Onciu, Elaine Coustan-Smith, Larry Kun, Sima Jeha, Cheng Cheng, Scott Howard, Vickey Simmons, Monika Metzger, James Boyett, Wing Leung and James Downing (St. Jude); W. Paul Bowman and Amy Bayles (Cook Children's Medical Center); and Rupert Handgretinger (formerly of St. Jude).
The research was supported in part by the National Institutes of Health, the American Cancer Society F.M. Kirby Clinical Research Professorship and ALSAC.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Ten
Page: 1 2 3 4 Related medicine technology :1
|SOURCE St. Jude Children's Research Hospital|
Copyright©2009 PR Newswire.
All rights reserved
. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice2
. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache3
. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)4
. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss5
. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia6
. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia7
. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial8
. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset9
. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients10
. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned11
. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache